These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36300147)

  • 1. Identifying optimal therapies in patients with advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
    Yang Z; Tong Y; Yang L; He X; Bao G; Du X
    Transl Gastroenterol Hepatol; 2022; 7():38. PubMed ID: 36300147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of interventional therapeutic modalities for unresectable hepatocellular carcinoma: A systematic review and network meta-analysis.
    Chen XL; Yu HC; Fan QG; Yuan Q; Jiang WK; Rui SZ; Zhou WC
    Oncol Lett; 2022 Oct; 24(4):366. PubMed ID: 36238837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis.
    Leung JH; Wang SY; Leung HWC; Chan ALF
    Front Oncol; 2024; 14():1344798. PubMed ID: 38434681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Katsanos K; Kitrou P; Spiliopoulos S; Maroulis I; Petsas T; Karnabatidis D
    PLoS One; 2017; 12(9):e0184597. PubMed ID: 28934265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Kim HJ; Lee SH; Shim HJ; Bang HJ; Cho SH; Chung IJ; Hwang EC; Hwang JE; Bae WK
    Front Oncol; 2023; 13():1265240. PubMed ID: 37881486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma.
    Liu BJ; Gao S; Zhu X; Guo JH; Zhang X; Chen H; Wang XD; Yang RJ
    World J Gastrointest Oncol; 2020 Jun; 12(6):663-676. PubMed ID: 32699581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
    Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
    BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion.
    Li MF; Leung HW; Chan AL; Wang SY
    Ther Clin Risk Manag; 2018; 14():1157-1168. PubMed ID: 30013351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of treatment regimens for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Chen QF; Wu PH; Huang T; Shen LJ; Huang ZL; Li W
    Medicine (Baltimore); 2019 Oct; 98(40):e17460. PubMed ID: 31577775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy of Interventional Therapies for Early-stage Hepatocellular Carcinoma: A PRISMA-compliant Systematic Review and Network Meta-analysis.
    Lan T; Chang L; Mn R; Wu L; Yuan YF
    Medicine (Baltimore); 2016 Apr; 95(15):e3185. PubMed ID: 27082558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk.
    Wu Z; Gao J; Zhuang W; Yang J; Guo W
    J Cancer Res Ther; 2022 Apr; 18(2):345-351. PubMed ID: 35645099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis.
    Si T; Huang Z; Khorsandi SE; Ma Y; Heaton N
    Front Bioeng Biotechnol; 2022; 10():1010824. PubMed ID: 36237208
    [No Abstract]   [Full Text] [Related]  

  • 13. Systemic therapy with or without locoregional therapy for advanced hepatocellular carcinoma: A systematic review and network meta-analysis.
    Ding ZN; Meng GX; Xue JS; Liu H; Yang LS; Li RZ; Mao XC; Yan YC; Wang DX; Dong ZR; Li T
    Crit Rev Oncol Hematol; 2023 Apr; 184():103940. PubMed ID: 36805079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma.
    Guo JH; Liu SX; Gao S; Kou FX; Zhang X; Wu D; Li XT; Chen H; Wang XD; Liu P; Zhang PJ; Xu HF; Cao G; Zhu LZ; Yang RJ; Zhu X
    World J Gastroenterol; 2020 Jul; 26(27):3975-3988. PubMed ID: 32774071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma.
    Ni JY; Liu SS; Xu LF; Sun HL; Chen YT
    World J Gastroenterol; 2013 Jun; 19(24):3872-82. PubMed ID: 23840128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
    Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials.
    Pan Y; Wang R; Hu D; Xie W; Fu Y; Hou J; Xu L; Zhang Y; Chen M; Zhou Z
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):873-881. PubMed ID: 34719212
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis.
    Dai Y; Jiang H; Jiang H; Zhao S; Zeng X; Sun R; Zheng R
    Transl Oncol; 2021 Dec; 14(12):101238. PubMed ID: 34628285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis.
    Jiang C; Cheng G; Liao M; Huang J
    World J Surg Oncol; 2021 Mar; 19(1):81. PubMed ID: 33741001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis.
    Salhab M; Canelo R
    J Cancer Res Ther; 2011; 7(4):463-75. PubMed ID: 22269411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.